ClinicalTrials.gg
CompletedNCT06323356Updated Nov 4, 2026Results posted

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

A Phase 3 interventional study of TAK-279 in Generalized Pustular Psoriasis and Erythrodermic Psoriasis, sponsored by Takeda. Completed at 20 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Updated Nov 4, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 109 studies in Psoriasis with a site in Japan — 5 open to participants now, 16 under way, 10 of them phase 3. Psoriasis · Japan.

Enrollment
90th of 97
18 · median 162
Started
2024
with 7 others
Phase 3
57 of 109
3 open now
Registered
97th of 109
by date

Among the 109 studies in Psoriasis with a site in Japan, this one is the 90th largest by enrollment of the 97 interventional ones that give a count, is one of 8 that started in 2024, is one of 57 in phase 3, and was the 97th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 109 studies in Psoriasis with a site in Japan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Psoriasis with a site in Japan, or all of them as a file.
02

Study summary

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279.

All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.

Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.

03

Conditions studied

  • Generalized Pustular Psoriasis
  • Erythrodermic Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of GPP or EP prior to the screening visit.
  2. Candidate for phototherapy or systemic therapy.

Exclusion criteria

Exclusion Criteria:

  1. Other forms of psoriasis.
  2. History of recent infection.
  3. Any prior exposure to TAK-279, or participation in any study that included a TYK2 inhibitor.

Other protocol defined inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    TAK-279 for Generalized Pustular Psoriasis

    Participants with generalized pustular psoriasis will receive TAK-279 from Day 1 up to Week 52.

    Drug: TAK-279

  • Experimental
    TAK-279 for Erythrodermic Psoriasis

    Participants with erythrodermic psoriasis will receive TAK-279 from Day 1 up to Week 52.

    Drug: TAK-279

Interventions

  • Specified drug on specified days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater Than or Equal to (>=) 2-Point Decrease From Baseline at Week 16

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1.

    Time frame: At Week 16

  2. Percentage of Participants Who Achieved >=75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score were reported.

    Time frame: At Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) With a >=2-Point Decrease From Baseline at Week 52

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

    Time frame: At Week 52

  2. Percentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) With a >=2-Point Decrease From Baseline at Both Weeks 16 and 52

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

    Time frame: At both Weeks 16 and 52

  3. Percentage of Participants Who Achieved an sPGA of Clear (0) at Weeks 16 and 52

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

  4. Percentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) at Weeks 16 and 52

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

  5. Percentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) at Both Weeks 16 and 52

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

    Time frame: At both Weeks 16 and 52

  6. Percentage of Participants Who Achieved PASI-75 at Week 52

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

    Time frame: At Week 52

  7. Percentage of Participants Who Achieved PASI-90 at Weeks 16 and 52

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

  8. Percentage of Participants Who Achieved PASI-100 at Weeks 16 and 52

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

  9. Percentage of Participants Who Achieved PASI-75 at Both Weeks 16 and 52

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

    Time frame: At both Weeks 16 and 52

  10. Percentage of Participants Who Achieved PASI-90 at Both Weeks 16 and 52

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

    Time frame: At both Weeks 16 and 52

  11. Percentage of Participants Who Achieved a Scalp-specific Physician's Global Assessment (ssPGA) of Absence of Disease (0) or Very Mild Disease (1) With a >=2-Point Decrease From Baseline at Weeks 16 and 52

    ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions were evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicated worsening. The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

  12. Change From Baseline in ssPGA at Weeks 16 and 52

    ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions were evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicated worsening. The results will be disclosed during final posting.

    Time frame: Baseline, Weeks 16 and 52

  13. Percentage of Participants Who Achieved a PGA of the Hands and/or Feet of Clear (0) or Almost Clear (1) With a >=2-Point Decrease From Baseline at Weeks 16 and 52

    PGA is a 5-point scale and a score of 0 to 4 was assigned, based on the category that best described the severity of active psoriasis of the participant's hands and feet, where 0=clear and 4=severe. Higher scores indicated worsening of severity. It was evaluated for participants with the presence of active hand or foot psoriasis on Day 1. The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

  14. Percentage of Participants With a Baseline Dermatology Life Quality Index (DLQI) Score >=2 Who Achieved DLQI Score of 0 or 1 at Weeks 16 and 52

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL) during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicated: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

  15. Change From Baseline in DLQI at Weeks 16 and 52

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL) during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicated: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). The results will be disclosed during final posting.

    Time frame: Baseline, Weeks 16 and 52

  16. Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Weeks 16 and 52 Among Participants With Nail Involvement at Baseline

    The NAPSI quantifies the severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on the lunula, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each nail was scored for both nail matrix and nail bed psoriasis for each quadrant (ranging from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all fingernails evaluated and ranged from 0 to 80. Higher scores indicated more severe psoriasis. The results will be disclosed during final posting.

    Time frame: Baseline, Weeks 16 and 52

  17. Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Weeks 16 and 52

    Psoriasis BSA was assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represented 1% BSA. The sum of handprints equated to the total surface area of involvement. The results will be disclosed during final posting.

    Time frame: Baseline, Weeks 16 and 52

  18. Percent Change From Baseline in BSA Affected by Psoriasis at Weeks 16 and 52

    Psoriasis BSA was assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represented 1% BSA. The sum of handprints equated to the total surface area of involvement. The results will be disclosed during final posting.

    Time frame: Baseline, Weeks 16 and 52

  19. Percentage of Participants With Generalized Pustular Psoriasis Who Achieved a Generalized Pustular Psoriasis Global Assessment (GPPGA) Pustulation Subscore of No Visible Pustules (0) at Weeks 16 and 52

    The GPPGA is a common endpoint in clinical studies of GPP and is a skin-based scoring system. The GPPGA is a clinician assessment of overall GPP severity based on a modified PGA. The severity of pustules, erythema, and scaling of GPP lesions was assessed. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The GPPGA score was based on averaging the individual scores for erythema, scaling, and pustulation and ranged from 0 to 4. Higher scores indicated more severe GPP. The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

  20. Percentage of Participants With Generalized Pustular Psoriasis Who Achieved a GPPGA of Clear (0) or Almost Clear (1) at Weeks 16 and 52

    The GPPGA is a common endpoint in clinical studies of GPP and is a skin-based scoring system. The GPPGA is a clinician assessment of overall GPP severity based on a modified PGA. The severity of pustules, erythema, and scaling of GPP lesions was assessed. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The GPPGA score was based on averaging the individual scores for erythema, scaling, and pustulation and ranged from 0 to 4. Higher scores indicated more severe GPP. The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

  21. Percentage of Participants With Generalized Pustular Psoriasis Who Achieved a GPPGA of Clear (0) at Weeks 16 and 52

    The GPPGA is a common endpoint in clinical studies of GPP and is a skin-based scoring system. The GPPGA is a clinician assessment of overall GPP severity based on a modified PGA. The severity of pustules, erythema, and scaling of GPP lesions was assessed. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The GPPGA score was based on averaging the individual scores for erythema, scaling, and pustulation and ranged from 0 to 4. Higher scores indicated more severe GPP. The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

  22. Percentage of Participants With Generalized Pustular Psoriasis Who Achieved >=75% Improvement From Baseline in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) Score at Weeks 16 and 52

    The GPPASI is a common endpoint in clinical studies of generalized pustular psoriasis (GPP) and is a skin-based scoring system. The GPPASI is a modified composite index and an adaptation of the PASI score. The induration component was substituted with a pustule component, with an overall score ranging from 0 (least severe) to 72 (most severe). Higher scores indicated more severe GPP. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The score for each body region was calculated as the product of the sum of severity scores and the corresponding BSA score for erythema, scaling, and pustulation, multiplied by a weighting factor for each body region. The total GPPASI score was determined as the sum of the individual scores from all body regions. The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

  23. Change From Baseline in Japanese Dermatological Association Severity Index (JDASI) Score at Weeks 16 and 52 for Participants With Generalized Pustular Psoriasis

    The Japanese Dermatological Association Severity Index (JDASI) assessed systemic symptoms based on laboratory changes. With the JDASI, the skin was evaluated using 3 criteria: (1) erythema area overall, (2) erythema area with pustules, and (3) oedema area. Scoring ranged from 3 to 0 (severe, moderate, mild, none), with a maximum of 9 points. For systemic involvement, pyrexia, white blood cell count, C-reactive protein (CRP), and serum albumin were assessed, with scores ranging from 2 to 0 and a maximum of 8 points. The total JDASI score for GPP was the sum of both categories and was categorized as severe (17-11 points), moderate (10-7 points), or mild (0-6 points). Higher scores indicated more severe GPP. The results will be disclosed during final posting.

    Time frame: At Weeks 16 and 52

07

Results

Posted Nov 4, 2026

Participant flow

Participants took part in the study at 20 investigative sites in Japan from 19 March 2024.

Participant flow — Overall Study
MilestoneTAK-279 for Generalized Pustular Psoriasis (GPP)TAK-279 for Erythrodermic Psoriasis (EP)
Started810
Completed49
Not completed41
Withdrew: Adverse event21
Withdrew: Lack of efficacy20

Outcome measures

PrimaryPercentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater Than or Equal to (>=) 2-Point Decrease From Baseline at Week 16

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater Than or Equal to (>=) 2-Point Decrease From Baseline at Week 16
percentage of participantsTAK-279 for GPPTAK-279 for EP
Percentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater Than or Equal to (>=) 2-Point Decrease From Baseline at Week 1633.380.0
PrimaryPercentage of Participants Who Achieved >=75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score were reported.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16
percentage of participantsTAK-279 for GPPTAK-279 for EP
Percentage of Participants Who Achieved >=75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 1637.580.0
SecondaryPercentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) With a >=2-Point Decrease From Baseline at Week 52

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

Time frame:
At Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) With a >=2-Point Decrease From Baseline at Both Weeks 16 and 52

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

Time frame:
At both Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved an sPGA of Clear (0) at Weeks 16 and 52

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) at Weeks 16 and 52

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) at Both Weeks 16 and 52

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

Time frame:
At both Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved PASI-75 at Week 52

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

Time frame:
At Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved PASI-90 at Weeks 16 and 52

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved PASI-100 at Weeks 16 and 52

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved PASI-75 at Both Weeks 16 and 52

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

Time frame:
At both Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved PASI-90 at Both Weeks 16 and 52

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

Time frame:
At both Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved a Scalp-specific Physician's Global Assessment (ssPGA) of Absence of Disease (0) or Very Mild Disease (1) With a >=2-Point Decrease From Baseline at Weeks 16 and 52

ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions were evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicated worsening. The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in ssPGA at Weeks 16 and 52

ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions were evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicated worsening. The results will be disclosed during final posting.

Time frame:
Baseline, Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved a PGA of the Hands and/or Feet of Clear (0) or Almost Clear (1) With a >=2-Point Decrease From Baseline at Weeks 16 and 52

PGA is a 5-point scale and a score of 0 to 4 was assigned, based on the category that best described the severity of active psoriasis of the participant's hands and feet, where 0=clear and 4=severe. Higher scores indicated worsening of severity. It was evaluated for participants with the presence of active hand or foot psoriasis on Day 1. The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With a Baseline Dermatology Life Quality Index (DLQI) Score >=2 Who Achieved DLQI Score of 0 or 1 at Weeks 16 and 52

The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL) during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicated: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in DLQI at Weeks 16 and 52

The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL) during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicated: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). The results will be disclosed during final posting.

Time frame:
Baseline, Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in Nail Psoriasis Severity Index (NAPSI) at Weeks 16 and 52 Among Participants With Nail Involvement at Baseline

The NAPSI quantifies the severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on the lunula, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each nail was scored for both nail matrix and nail bed psoriasis for each quadrant (ranging from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all fingernails evaluated and ranged from 0 to 80. Higher scores indicated more severe psoriasis. The results will be disclosed during final posting.

Time frame:
Baseline, Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Weeks 16 and 52

Psoriasis BSA was assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represented 1% BSA. The sum of handprints equated to the total surface area of involvement. The results will be disclosed during final posting.

Time frame:
Baseline, Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in BSA Affected by Psoriasis at Weeks 16 and 52

Psoriasis BSA was assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represented 1% BSA. The sum of handprints equated to the total surface area of involvement. The results will be disclosed during final posting.

Time frame:
Baseline, Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Generalized Pustular Psoriasis Who Achieved a Generalized Pustular Psoriasis Global Assessment (GPPGA) Pustulation Subscore of No Visible Pustules (0) at Weeks 16 and 52

The GPPGA is a common endpoint in clinical studies of GPP and is a skin-based scoring system. The GPPGA is a clinician assessment of overall GPP severity based on a modified PGA. The severity of pustules, erythema, and scaling of GPP lesions was assessed. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The GPPGA score was based on averaging the individual scores for erythema, scaling, and pustulation and ranged from 0 to 4. Higher scores indicated more severe GPP. The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Generalized Pustular Psoriasis Who Achieved a GPPGA of Clear (0) or Almost Clear (1) at Weeks 16 and 52

The GPPGA is a common endpoint in clinical studies of GPP and is a skin-based scoring system. The GPPGA is a clinician assessment of overall GPP severity based on a modified PGA. The severity of pustules, erythema, and scaling of GPP lesions was assessed. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The GPPGA score was based on averaging the individual scores for erythema, scaling, and pustulation and ranged from 0 to 4. Higher scores indicated more severe GPP. The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Generalized Pustular Psoriasis Who Achieved a GPPGA of Clear (0) at Weeks 16 and 52

The GPPGA is a common endpoint in clinical studies of GPP and is a skin-based scoring system. The GPPGA is a clinician assessment of overall GPP severity based on a modified PGA. The severity of pustules, erythema, and scaling of GPP lesions was assessed. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The GPPGA score was based on averaging the individual scores for erythema, scaling, and pustulation and ranged from 0 to 4. Higher scores indicated more severe GPP. The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Generalized Pustular Psoriasis Who Achieved >=75% Improvement From Baseline in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) Score at Weeks 16 and 52

The GPPASI is a common endpoint in clinical studies of generalized pustular psoriasis (GPP) and is a skin-based scoring system. The GPPASI is a modified composite index and an adaptation of the PASI score. The induration component was substituted with a pustule component, with an overall score ranging from 0 (least severe) to 72 (most severe). Higher scores indicated more severe GPP. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The score for each body region was calculated as the product of the sum of severity scores and the corresponding BSA score for erythema, scaling, and pustulation, multiplied by a weighting factor for each body region. The total GPPASI score was determined as the sum of the individual scores from all body regions. The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in Japanese Dermatological Association Severity Index (JDASI) Score at Weeks 16 and 52 for Participants With Generalized Pustular Psoriasis

The Japanese Dermatological Association Severity Index (JDASI) assessed systemic symptoms based on laboratory changes. With the JDASI, the skin was evaluated using 3 criteria: (1) erythema area overall, (2) erythema area with pustules, and (3) oedema area. Scoring ranged from 3 to 0 (severe, moderate, mild, none), with a maximum of 9 points. For systemic involvement, pyrexia, white blood cell count, C-reactive protein (CRP), and serum albumin were assessed, with scores ranging from 2 to 0 and a maximum of 8 points. The total JDASI score for GPP was the sum of both categories and was categorized as severe (17-11 points), moderate (10-7 points), or mild (0-6 points). Higher scores indicated more severe GPP. The results will be disclosed during final posting.

Time frame:
At Weeks 16 and 52

Results for this outcome have not been posted.

Adverse events

Collected over From start of study drug administration up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAK-279 for GPP0/8 (0%)2/8 (25%)8/8 (100%)
TAK-279 for EP0/10 (0%)1/10 (10%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventTAK-279 for GPPTAK-279 for EP
Cardiac failure congestiveCardiac disorders1/80/10
DehydrationMetabolism and nutrition disorders1/80/10
FallInjury, poisoning and procedural complications1/80/10
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/80/10
Device dislocationProduct Issues0/81/10
Most frequent other events
Showing 10 of 52
Most frequent other events
EventTAK-279 for GPPTAK-279 for EP
Eosinophil count increasedInvestigations3/80/10
NasopharyngitisInfections and infestations2/83/10
Alcoholic liver diseaseHepatobiliary disorders0/82/10
COVID-19Infections and infestations0/82/10
Skin erosionSkin and subcutaneous tissue disorders0/82/10
Albumin urine presentInvestigations1/80/10
AnaemiaBlood and lymphatic system disorders1/81/10
BlepharitisEye disorders1/80/10
CheilitisGastrointestinal disorders1/80/10
Chemokine increasedInvestigations1/80/10

Baseline characteristics

Safety Analysis Set (SAS) included participants who received any dose of TAK-279.

Age, Categorical
Age, Categorical(Participants)TAK-279 for GPPTAK-279 for EPTotal
<=18 years000
Between 18 and 65 years6713
>=65 years235
Sex: Female, Male
Sex: Female, Male(Participants)TAK-279 for GPPTAK-279 for EPTotal
Female415
Male4913
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)TAK-279 for GPPTAK-279 for EPTotal
Count of participants——0
08

Study locations

20 sites
  • Nagoya City University Hospital
    Nagoya, Aichi-ken, Japan
  • Fujita Health University Hospital
    Toyoake, Aichi-ken, Japan
  • Kimitsu Chuo Hospital
    Kisarazu, Chiba, Japan
  • Juntendo University Urayasu Hospital
    Urayasu, Chiba, Japan
  • Hospital of the University of Occupational and Environmental Health, Japan
    Kitakyushu, Fukuoka, Japan
  • Isesaki Municipal Hospital
    Isesaki, Gunma, Japan
  • Kobe University Hospital
    Kobe, Hyōgo, Japan
  • Tokai University Hospital
    Isehara, Kanagawa, Japan
  • Mie University Hospital
    Tsu, Mie-ken, Japan
  • Kansai Medical University Hospital
    Hirakata, Osaka, Japan
  • Saitama Medical University Hospital
    Iruma, Saitama, Japan
  • St.Luke's International Hospital
    Chūō, Tokyo, Japan
  • The Jikei University Hospital
    Minato-ku, Tokyo, Japan
  • Tokyo Medical University Hospital
    Shinjuku-ku, Tokyo, Japan
  • Teikyo University Hospital
    tabashi City, Tokyo, Japan
  • Fukuoka University Hospital
    Fukuoka, Japan
  • University Hospital, Kyoto Prefectural University of Medicine
    Kyoto, Japan
  • Okayama University Hospital
    Okayama, Japan
  • Nippon Life Hospital
    Osaka, Japan
  • Osaka Metropolitan University Hospital
    Osaka, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Oct 2025, 18 months.

Results were first posted in Nov 2026, 1 year after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Mar 21, 2024
StartActual
Mar 19, 2024
Primary completionActual
Oct 17, 2025
CompletionActual
Jul 10, 2026
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Sites
1 site added, 1 site removed
Show site
  • Teikyo University Hospital · tabashi City, Japan
Show 1 removed
  • Teikyo University Hospital · Itabashi-ku, Japan
Nov 4, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPercentage of Participants AchievingWho Achieved a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a ≥Greater Than or Equal to (>=) 2-Point Decrease fromFrom Baseline at Week 16Time frame: Baseline, Week 16 → At Week 16
  • EditedPercentage of Participants Achieving ≥Who Achieved >=75 Percent (%) Improvement fromFrom Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16Time frame: Baseline, Week 16 → At Week 16
Nov 4, 2026
Documents
Secondary outcomes
22 edited, 1 added
What changed in the outcomes
  • EditedPercentage of Participants AchievingWho Achieved an sPGA of Clear (0) or Almost Clear (1) With a ≥>=2-Point Decrease fromFrom Baseline at Week 52Time frame: Baseline, Week 52 → At Week 52
  • EditedPercentage of Participants AchievingWho Achieved an sPGA of Clear (0) or Almost Clear (1) With a ≥>=2-Point Decrease fromFrom Baseline at Both WeekWeeks 16 and Week 52 VisitsTime frame: Baseline, Week 16 and Week 52 → At both Weeks 16 and 52
  • EditedPercentage of Participants AchievingWho Achieved an sPGA of Clear (0) at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
  • EditedPercentage of Participants AchievingWho Achieved an sPGA of Clear (0) or Almost Clear (1) at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
  • EditedPercentage of Participants AchievingWho Achieved an sPGA of Clear (0) or Almost Clear (1) at WeekBoth Weeks 16 and Week 52 VisitsTime frame: Week 16 and Week 52 → At both Weeks 16 and 52
  • EditedPercentage of Participants AchievingWho Achieved PASI-75 at Week 52Time frame: Week 52 → At Week 52
  • EditedPercentage of Participants AchievingWho Achieved PASI-90 at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
  • EditedPercentage of Participants AchievingWho Achieved PASI-100 at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
  • EditedPercentage of Participants AchievingWho Achieved PASI-75 at Both the WeekWeeks 16 and Week 52 VisitsTime frame: Week 16 and Week 52 → At both Weeks 16 and 52
  • EditedPercentage of Participants AchievingWho Achieved PASI-90 at Both the WeekWeeks 16 and Week 52 VisitsTime frame: Week 16 and Week 52 → At both Weeks 16 and 52
  • EditedPercentage of Participants AchievingWho Achieved a Scalp-specific Physician's Global Assessment (ssPGA) of Absence of Disease (0) or Very Mild Disease (1) With a ≥>=2-Point Decrease fromFrom Baseline at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
  • EditedChange from baselineFrom Baseline in ssPGA at Weeks 16 and 52Time frame: Baseline, Week 16 and Week 52 → Baseline, Weeks 16 and 52
  • EditedPercentage of Participants AchievingWho Achieved a PGA of the Hands and/or Feet of Clear (0) or Almost Clear (1) With a ≥>=2-Point Decrease fromFrom Baseline at Weeks 16 and Week 52Time frame: Baseline, Week 16 and Week 52 → At Weeks 16 and 52
  • EditedPercentage of Participants withWith a Baseline Dermatology Life Quality Index (DLQI) Score ≥>=2 who AchieveWho Achieved DLQI Score of 0 or 1 at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
  • EditedChange fromFrom Baseline in DLQI at WeekWeeks 16 and Week 52Time frame: Baseline, Week 16 and Week 52 → Baseline, Weeks 16 and 52
  • EditedChange fromFrom Baseline in Nail Psoriasis Severity Index (NAPSI) at WeekWeeks 16 and Week 52 Among Participants withWith Nail Involvement at BaselineTime frame: Baseline, Week 16 and Week 52 → Baseline, Weeks 16 and 52
  • EditedChange fromFrom Baseline in Body Surface Area (BSA) Affected by Psoriasis at WeekWeeks 16 and Week 52Time frame: Baseline, Week 16 and Week 52 → Baseline, Weeks 16 and 52
  • EditedPercentage of Participants withWith Generalized Pustular Psoriasis Who AchieveAchieved a Generalized Pustular Psoriasis Global Assessment (GPPGA) Pustulation Subscore of No Visible Pustules (0) at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
  • EditedPercentage of Participants withWith Generalized Pustular Psoriasis Who AchieveAchieved a GPPGA of Clear (0) or Almost Clear (1) at Weeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
  • EditedPercentage of Participants withWith Generalized Pustular Psoriasis Who AchieveAchieved a GPPGA of Clear (0) at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
  • EditedPercentage of Participants withWith Generalized Pustular Psoriasis Who Achieve ≥Achieved >=75% Improvement fromFrom Baseline in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) Score at WeekWeeks 16 and Week 52Time frame: Weeks 16 and Week 52 → At Weeks 16 and 52
  • EditedChange fromFrom Baseline in Japanese Dermatological Association Severity Index (JDASI) Score at WeekWeeks 16 and Week 52 for Participants withWith Generalized Pustular PsoriasisTime frame: Week 16 and Week 52 → At Weeks 16 and 52
  • AddedPercent Change From Baseline in BSA Affected by Psoriasis at Weeks 16 and 52Time frame: Baseline, Weeks 16 and 52
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Teikyo University Hospital · tabashi City, Japan
    Show 1 removed
    • Teikyo University Hospital · Itabashi-ku, Japan
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPercentage of Participants AchievingWho Achieved a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a ≥Greater Than or Equal to (>=) 2-Point Decrease fromFrom Baseline at Week 16Time frame: Baseline, Week 16 → At Week 16
    • EditedPercentage of Participants Achieving ≥Who Achieved >=75 Percent (%) Improvement fromFrom Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16Time frame: Baseline, Week 16 → At Week 16
    Secondary outcomes 22 edited, 1 added
    What changed in the outcomes
    • EditedPercentage of Participants AchievingWho Achieved an sPGA of Clear (0) or Almost Clear (1) With a ≥>=2-Point Decrease fromFrom Baseline at Week 52Time frame: Baseline, Week 52 → At Week 52
    • EditedPercentage of Participants AchievingWho Achieved an sPGA of Clear (0) or Almost Clear (1) With a ≥>=2-Point Decrease fromFrom Baseline at Both WeekWeeks 16 and Week 52 VisitsTime frame: Baseline, Week 16 and Week 52 → At both Weeks 16 and 52
    • EditedPercentage of Participants AchievingWho Achieved an sPGA of Clear (0) at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
    • EditedPercentage of Participants AchievingWho Achieved an sPGA of Clear (0) or Almost Clear (1) at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
    • EditedPercentage of Participants AchievingWho Achieved an sPGA of Clear (0) or Almost Clear (1) at WeekBoth Weeks 16 and Week 52 VisitsTime frame: Week 16 and Week 52 → At both Weeks 16 and 52
    • EditedPercentage of Participants AchievingWho Achieved PASI-75 at Week 52Time frame: Week 52 → At Week 52
    • EditedPercentage of Participants AchievingWho Achieved PASI-90 at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
    • EditedPercentage of Participants AchievingWho Achieved PASI-100 at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
    • EditedPercentage of Participants AchievingWho Achieved PASI-75 at Both the WeekWeeks 16 and Week 52 VisitsTime frame: Week 16 and Week 52 → At both Weeks 16 and 52
    • EditedPercentage of Participants AchievingWho Achieved PASI-90 at Both the WeekWeeks 16 and Week 52 VisitsTime frame: Week 16 and Week 52 → At both Weeks 16 and 52
    • EditedPercentage of Participants AchievingWho Achieved a Scalp-specific Physician's Global Assessment (ssPGA) of Absence of Disease (0) or Very Mild Disease (1) With a ≥>=2-Point Decrease fromFrom Baseline at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
    • EditedChange from baselineFrom Baseline in ssPGA at Weeks 16 and 52Time frame: Baseline, Week 16 and Week 52 → Baseline, Weeks 16 and 52
    • EditedPercentage of Participants AchievingWho Achieved a PGA of the Hands and/or Feet of Clear (0) or Almost Clear (1) With a ≥>=2-Point Decrease fromFrom Baseline at Weeks 16 and Week 52Time frame: Baseline, Week 16 and Week 52 → At Weeks 16 and 52
    • EditedPercentage of Participants withWith a Baseline Dermatology Life Quality Index (DLQI) Score ≥>=2 who AchieveWho Achieved DLQI Score of 0 or 1 at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
    • EditedChange fromFrom Baseline in DLQI at WeekWeeks 16 and Week 52Time frame: Baseline, Week 16 and Week 52 → Baseline, Weeks 16 and 52
    • EditedChange fromFrom Baseline in Nail Psoriasis Severity Index (NAPSI) at WeekWeeks 16 and Week 52 Among Participants withWith Nail Involvement at BaselineTime frame: Baseline, Week 16 and Week 52 → Baseline, Weeks 16 and 52
    • EditedChange fromFrom Baseline in Body Surface Area (BSA) Affected by Psoriasis at WeekWeeks 16 and Week 52Time frame: Baseline, Week 16 and Week 52 → Baseline, Weeks 16 and 52
    • EditedPercentage of Participants withWith Generalized Pustular Psoriasis Who AchieveAchieved a Generalized Pustular Psoriasis Global Assessment (GPPGA) Pustulation Subscore of No Visible Pustules (0) at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
    • EditedPercentage of Participants withWith Generalized Pustular Psoriasis Who AchieveAchieved a GPPGA of Clear (0) or Almost Clear (1) at Weeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
    • EditedPercentage of Participants withWith Generalized Pustular Psoriasis Who AchieveAchieved a GPPGA of Clear (0) at WeekWeeks 16 and Week 52Time frame: Week 16 and Week 52 → At Weeks 16 and 52
    • EditedPercentage of Participants withWith Generalized Pustular Psoriasis Who Achieve ≥Achieved >=75% Improvement fromFrom Baseline in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) Score at WeekWeeks 16 and Week 52Time frame: Weeks 16 and Week 52 → At Weeks 16 and 52
    • EditedChange fromFrom Baseline in Japanese Dermatological Association Severity Index (JDASI) Score at WeekWeeks 16 and Week 52 for Participants withWith Generalized Pustular PsoriasisTime frame: Week 16 and Week 52 → At Weeks 16 and 52
    • AddedPercent Change From Baseline in BSA Affected by Psoriasis at Weeks 16 and 52Time frame: Baseline, Weeks 16 and 52
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06323356
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Mar 19, 2024
Primary completion
Oct 17, 2025
Completion
Jul 10, 2026
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zasocitinib

Start the discussion